首页|骨肉瘤驱动基因与免疫微环境及靶向治疗的研究进展

骨肉瘤驱动基因与免疫微环境及靶向治疗的研究进展

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Research advances on osteosarcoma driver genes,immune microenvironment,and targeted therapy
The 5-year survival rate of osteosarcoma(OS),the most common malignant bone tumor,has remained unchanged at 60%-70%for nearly 40 years.Its treatment mainly relies on surgical resection combined with multi-drug chemotherapy,but it is ineffective for patients with metastasis.In recent years,a series of clinical trials conducted around the world have not effectively improved the 5-year survival rate.However,along with the development of gene sequencing technology and related biomedicines,and the progress of precision medicine,a lot of progress has been made in the research of osteosarcoma driver genes,immune microenvironment,and targeted therapy.In this review,the research progress of osteosarcoma in terms of driver genes,immune microenvironment,and targeted therapy is expounded.

OsteosarcomaMolecular targeted therapyCellular microenvironmentDriver genesReview

刘净峰、徐鸿锋、刘巍峰

展开 >

100035 北京,首都医科大学附属北京积水潭医院骨肿瘤科

骨肉瘤 分子靶向治疗 细胞微环境 驱动基因 综述

国家重点研发计划国家重点研发计划北京市自然科学基金北京市市属医院科研培育项目北京积水潭医院"学科骨干"计划专项北京积水潭医院院级科研基金

2023YFB47063002021YFC2400500L212042PX2021015XKGG2021052023OSR-GCZX202206

2024

10.3969/j.issn.2095-252X.2024.05.013

中国骨与关节杂志
中国医疗保健国际交流促进会，北京中科康辰骨关节伤病研究所

中国骨与关节杂志

CSTPCD
影响因子：0.665
ISSN：2095-252X
年,卷(期)：2024.13(5)
  • 1
  • 2